HCW Biologics Inc. (HCWB)
Company Description
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases.
The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.
It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia.
The company was incorporated in 2018 and is headquartered in Miramar, Florida.
| Country | United States |
| IPO Date | Jul 20, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Dr. Hing C. Wong Ph.D. |
Contact Details
Address: 2929 North Commerce Parkway Miramar, Florida United States | |
| Website | https://www.hcwbiologics.com |
Stock Details
| Ticker Symbol | HCWB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001828673 |
| CUSIP Number | 40423R105 |
| ISIN Number | US40423R1059 |
| Employer ID | 82-5024477 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hing C. Wong Ph.D. | Founder, Chief Executive Officer, Director & Secretary |
| Dr. Peter Rhode Ph.D. | Chief Scientific Officer & Vice President of Clinical Operations |
| Lee D. Flowers | Senior Vice President of Business Development |
| Nicole Valdivieso Esq. | Vice President of Legal Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | DEF 14A | Filing |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Filing |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 16, 2025 | 424B3 | Filing |
| Apr 14, 2025 | 8-K | Current Report |
| Apr 07, 2025 | S-1 | Filing |
| Apr 01, 2025 | 8-K | Current Report |
| Apr 01, 2025 | 8-K | Current Report |
| Mar 28, 2025 | 10-K | Annual Report |